In CRC, targeting LAG-3 or TIM-3 in combination with PD-1 or CTLA-4 blockade could potentially synergize to overcome Treg-mediated immunosuppression, thereby enhancing antitumor immunity (86, 93). The gene discussed is PDCD1; the disease is colorectal carcinoma.